Nature Communications (Feb 2022)
Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer
- Ziyang Xu,
- Susanne Walker,
- Megan C. Wise,
- Neethu Chokkalingam,
- Mansi Purwar,
- Alan Moore,
- Edgar Tello-Ruiz,
- Yuanhan Wu,
- Sonali Majumdar,
- Kylie M. Konrath,
- Abhijeet Kulkarni,
- Nicholas J. Tursi,
- Faraz I. Zaidi,
- Emma L. Reuschel,
- Ishaan Patel,
- April Obeirne,
- Jianqiu Du,
- Katherine Schultheis,
- Lauren Gites,
- Trevor Smith,
- Janess Mendoza,
- Kate E. Broderick,
- Laurent Humeau,
- Jesper Pallesen,
- David B. Weiner,
- Daniel W. Kulp
Affiliations
- Ziyang Xu
- Vaccine and Immunotherapy Center, The Wistar Institute
- Susanne Walker
- Vaccine and Immunotherapy Center, The Wistar Institute
- Megan C. Wise
- Inovio Pharmaceuticals
- Neethu Chokkalingam
- Vaccine and Immunotherapy Center, The Wistar Institute
- Mansi Purwar
- Vaccine and Immunotherapy Center, The Wistar Institute
- Alan Moore
- Molecular and Cellular Biochemistry, Indiana University
- Edgar Tello-Ruiz
- Vaccine and Immunotherapy Center, The Wistar Institute
- Yuanhan Wu
- Vaccine and Immunotherapy Center, The Wistar Institute
- Sonali Majumdar
- Vaccine and Immunotherapy Center, The Wistar Institute
- Kylie M. Konrath
- Vaccine and Immunotherapy Center, The Wistar Institute
- Abhijeet Kulkarni
- Vaccine and Immunotherapy Center, The Wistar Institute
- Nicholas J. Tursi
- Vaccine and Immunotherapy Center, The Wistar Institute
- Faraz I. Zaidi
- Vaccine and Immunotherapy Center, The Wistar Institute
- Emma L. Reuschel
- Vaccine and Immunotherapy Center, The Wistar Institute
- Ishaan Patel
- Vaccine and Immunotherapy Center, The Wistar Institute
- April Obeirne
- Vaccine and Immunotherapy Center, The Wistar Institute
- Jianqiu Du
- Molecular and Cellular Biochemistry, Indiana University
- Katherine Schultheis
- Inovio Pharmaceuticals
- Lauren Gites
- Inovio Pharmaceuticals
- Trevor Smith
- Inovio Pharmaceuticals
- Janess Mendoza
- Inovio Pharmaceuticals
- Kate E. Broderick
- Inovio Pharmaceuticals
- Laurent Humeau
- Inovio Pharmaceuticals
- Jesper Pallesen
- Molecular and Cellular Biochemistry, Indiana University
- David B. Weiner
- Vaccine and Immunotherapy Center, The Wistar Institute
- Daniel W. Kulp
- Vaccine and Immunotherapy Center, The Wistar Institute
- DOI
- https://doi.org/10.1038/s41467-022-28363-z
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 18
Abstract
HIV envelope is a target for vaccine development, but induction of broadly neutralizing antibodies has been difficult. Here, the authors show that electroporation with a synthetic DNA vaccine construct allows in vivo production of HIV envelope native like trimers to induce autologous tier-2 neutralizing antibodies targeting a C3/V5 epitope in mice.
